Document is current
Any future updates will be listed below
-
Authors
Kelly Graves, Occam https://orcid.org/0000-0003-3978-9750
Kang, Jiayi
Li, Haobo
Erdin, Serkan https://orcid.org/0000-0001-6587-2625
Smith, Matthew
Mueller, Ariel
Simon, Christopher
Wiredu, Kwame https://orcid.org/0000-0003-1519-1586
Bhave, Varun
De Esch, Celine
Lemanski, John
Talkowski, Michael E.
Rhee, James https://orcid.org/0000-0002-2181-4957
Qu, Jason
McKay, Tina B. https://orcid.org/0000-0003-0130-9272
Akeju, Oluwaseun https://orcid.org/0000-0002-6740-1250
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R21AG073750, R01AG053582, R21AG073750)
- License Information
-
More Information
Article History
Received: 29 July 2024
Revised: 8 May 2025
Accepted: 19 May 2025
First Online: 27 May 2025
Competing interests
: A.M. reports receiving funding from Roche Diagnostics, the Preeclampsia Foundation and the University of Chicago for statistical consulting projects related to biomarkers in preeclampsia. O.A. holds patents on anesthetic state monitoring and has received royalties from intellectual property through Massachusetts General Hospital licensed to Masimo. O.A. is a scientific consultant in Reversal Therapeutics and holds equity. The interests of O.A. were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.
: All experiments were performed in accordance with relevant guidelines and regulations approved by the MGB Institutional Review Board (IRB Protocol # 2016P000742). All subjects provided written informed consent prior to enrollment in the parent trial.
